Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia
about
Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studiesSafety and efficacy of colesevelam HCl in the treatment of elderly patientsChitosan oligosaccharide improves the therapeutic efficacy of sitagliptin for the therapy of Chinese elderly patients with type 2 diabetes mellitus.Disease burden evaluation of fall-related events in the elderly due to hypoglycemia and other diabetic complications: a clinical review.Incidence and predictors of hypoglycaemia in type 2 diabetes - an analysis of the prospective DiaRegis registry.Unanswered clinical questions in the management of cardiometabolic risk in the elderly: a statement of the Spanish Society of Internal Medicine.Hypoglycemia in older people - a less well recognized risk factor for frailtyAge-related metabolic fatigue during low glucose conditions in rat hippocampus.Predictors for Mild and Severe Hypoglycemia in Insulin-Treated Japanese Diabetic Patients.Potential glycemic overtreatment in patients ≥75 years with type 2 diabetes mellitus and renal disease: experience from the observational OREDIA study.A consumer-targeted, pharmacist-led, educational intervention to reduce inappropriate medication use in community older adults (D-PRESCRIBE trial): study protocol for a cluster randomized controlled trialCo-morbidity but not dysglycaemia reduces quality of life in patients with type-2 diabetes treated with oral mono- or dual combination therapy--an analysis of the DiaRegis registryManagement of type 2 diabetes in older peopleLong-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III StudiesCardiac implications of hypoglycaemia in patients with diabetes - a systematic reviewManagement of type 2 diabetes mellitus in older patients: current and emerging treatment options.Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes.Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial.Direct medical costs of severe hypoglycaemic events in patients with type 2 diabetes in England: A retrospective database study.Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis.Examining factors associated with excess mortality in older people (age ≥ 70 years) with diabetes - a 10-year cohort study of older people with and without diabetes.Incidence, characteristics and impact of hypoglycaemia in patients receiving intensified treatment for inadequately controlled type 2 diabetes mellitus.A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus.Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.Hypoglycemia is independently associated with multidimensional impairment in elderly diabetic patients.Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies.Association of physical activity with glycaemic control and cardiovascular risk profile in 65 666 people with type 2 diabetes from Germany and Austria.Meglitinides increase the risk of hypoglycemia in diabetic patients with advanced chronic kidney disease: a nationwide, population-based study.Inadequate Glycaemic Control and Therapeutic Management of Adults over 65 Years Old with Type 2 Diabetes Mellitus in Spain.Comorbidity of chronic kidney disease, diabetes and lower glycated hemoglobin predicts support/care-need certification in community-dwelling older adults.Insulin Glargine Combined with Oral Antidiabetic Drugs for Asians with Type 2 Diabetes Mellitus: A Pooled Analysis to Identify Predictors of Dose and Treatment Response.The current status of treatment-related severe hypoglycemia in Japanese patients with diabetes mellitus: A report from the committee on a survey of severe hypoglycemia in the Japan Diabetes Society.Glycemic control and disability-free survival in hypoglycemic agent-treated community-dwelling older patients with type 2 diabetes mellitus.
P2860
Q33613143-AAD1117D-B083-4F80-8831-54EBBB0A2C51Q33663484-0D8E94C5-F293-484E-BDBD-BF51726CFCA9Q33878811-20F92B14-769E-41C5-9C15-50603FDC53B0Q34073775-080B0B67-A2C8-4D5C-AFC0-4798A583DEF2Q34449517-327CE3AE-00E6-4C16-9252-BF3D8F311918Q34901444-2142DC2A-727B-4053-AFD2-B662D76A437EQ35195244-DE81DFD5-4467-4CD6-92DA-69E91B1E3C16Q35646715-D4378BD8-C965-4500-84ED-DE162EFD0F0DQ35671692-BF2EA244-C55B-4DF8-8F71-113EEF2CAFA7Q35841565-F4BFDDCB-476F-481D-A01C-0C7C2052BFAAQ35881312-89DD6861-57C2-493D-8402-F4F9F630C626Q36711917-DD17844F-BED1-49A5-99CE-ECA3F8CEFC82Q36941718-BE6E8611-21A3-4301-B39A-E2CB97D7D2A7Q37075620-CA0313D8-011D-4D73-B633-FE8A94A5AA2AQ37361386-D397D1B7-9C09-42AF-AB27-2E129629AE74Q37468429-E0B3AEA9-0984-4455-BFD0-DD6BA2760057Q38215452-ADFF9F18-0F4A-413D-AB7D-B30EB7390C31Q38410465-9BAD8342-8C30-474C-9035-3AD3D717DC99Q38764131-2699E713-0AD9-4B9B-B7DA-804AF3BBD960Q39157386-C1B781EC-C7F2-4158-B66A-162652E7A34DQ39844000-CD9125DA-992A-4ED9-8F62-024942413861Q41124412-B4F52413-2F57-4C35-AAB8-7AFB16DAE307Q41477500-EA3B3E94-7489-4D81-A601-7AFF2D204978Q41605742-8D0DF920-BB59-4034-921A-2AB55886782EQ41791225-EE6F3DDC-8969-49AC-BE00-19C49838F99FQ44452805-428FF4B2-F916-4EED-BEFE-C5E38B6E1D2FQ44548336-9ACA38C5-CE27-418E-B49B-234803B944E8Q45738296-F0088325-8053-4AA8-8963-7598A1F1262EQ47145533-5EF2CB75-96C1-419C-8A0D-3DB9A7F5FB48Q47393240-DF86BE9E-57D0-434D-BFE6-8491A956E890Q48119986-B31C128C-CD5E-4A08-9CA2-3D108A2E7295Q51245623-98F1EF6C-5EAF-42E7-9AB1-C636553DFC16Q52677620-AC775744-5302-4D7A-8FAE-AAE4664CC607Q53511750-9B7E3E66-9A03-4C41-9896-372ECCE31395
P2860
Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Oral antidiabetic treatment in ...... l and the risk of hypoglycemia
@ast
Oral antidiabetic treatment in ...... l and the risk of hypoglycemia
@en
type
label
Oral antidiabetic treatment in ...... l and the risk of hypoglycemia
@ast
Oral antidiabetic treatment in ...... l and the risk of hypoglycemia
@en
prefLabel
Oral antidiabetic treatment in ...... l and the risk of hypoglycemia
@ast
Oral antidiabetic treatment in ...... l and the risk of hypoglycemia
@en
P2093
P2860
P921
P356
P1476
Oral antidiabetic treatment in ...... l and the risk of hypoglycemia
@en
P2093
Anselm K Gitt
Christiane Binz
Diethelm Tschöpe
Evelin Deeg
Michael Krekler
P2860
P2888
P356
10.1186/1475-2840-11-122
P407
P577
2012-10-06T00:00:00Z
P5875
P6179
1039394781